Złotek Magdalena, Kurowska Antonina, Herbet Mariola, Piątkowska-Chmiel Iwona
Department of Toxicology, Faculty of Pharmacy, Medical University of Lublin, Jaczewskiego 8b Street, 20-090 Lublin, Poland.
Biomedicines. 2023 Nov 12;11(11):3035. doi: 10.3390/biomedicines11113035.
Alzheimer's is a prevalent, progressive neurodegenerative disease marked by cognitive decline and memory loss. The disease's development involves various pathomechanisms, including amyloid-beta accumulation, neurofibrillary tangles, oxidative stress, inflammation, and mitochondrial dysfunction. Recent research suggests that antidiabetic drugs may enhance neuronal survival and cognitive function in diabetes. Given the well-documented correlation between diabetes and Alzheimer's disease and the potential shared mechanisms, this review aimed to comprehensively assess the potential of new-generation anti-diabetic drugs, such as GLP-1 analogs, SGLT-2 inhibitors, and DPP-4 inhibitors, as promising therapeutic approaches for Alzheimer's disease. This review aims to comprehensively assess the potential therapeutic applications of novel-generation antidiabetic drugs, including GLP-1 analogs, SGLT-2 inhibitors, and DPP-4 inhibitors, in the context of Alzheimer's disease. In our considered opinion, antidiabetic drugs offer a promising avenue for groundbreaking developments and have the potential to revolutionize the landscape of Alzheimer's disease treatment.
阿尔茨海默病是一种常见的、进行性神经退行性疾病，其特征为认知能力下降和记忆力丧失。该疾病的发展涉及多种病理机制，包括β-淀粉样蛋白积累、神经原纤维缠结、氧化应激、炎症和线粒体功能障碍。最近的研究表明，抗糖尿病药物可能会提高糖尿病患者的神经元存活率和认知功能。鉴于糖尿病与阿尔茨海默病之间有充分记录的相关性以及潜在的共同机制，本综述旨在全面评估新一代抗糖尿病药物，如胰高血糖素样肽-1（GLP-1）类似物、钠-葡萄糖协同转运蛋白2（SGLT-2）抑制剂和二肽基肽酶-4（DPP-4）抑制剂，作为阿尔茨海默病有前景的治疗方法的潜力。本综述旨在全面评估新一代抗糖尿病药物，包括GLP-1类似物、SGLT-2抑制剂和DPP-4抑制剂，在阿尔茨海默病背景下的潜在治疗应用。我们认为，抗糖尿病药物为开创性发展提供了一条有前景的途径，并有潜力彻底改变阿尔茨海默病的治疗格局。
Zotero 插件